Sinil Pharma Q1 2026: Revenue Up but Profit Down; Solid Financials
Q1 2026 (Jan-Mar): Revenue KRW 20.9B (up 8.4% from previous quarter, up from KRW 19.2B in Q1 2025), operating profit KRW 1.33B (down from KRW 1.99B), net profit KRW 1.44B (down from KRW 2.02B)
Debt ratio 6.3%, no borrowings, cash and equivalents KRW 8.32B
R&D cost KRW 1.34B (6.4% of revenue), pipeline includes SIL1102 (anticoagulant) approved
Treasury shares 426,854 (3.56% of total), no changes in dividend policy